Cell cycle

Acrivon Therapeutics Presents Data at AACR Annual Meeting Highlighting the Capabilities of Acrivon Predictive Precision Proteomics (AP3) for the Discovery of ACR-2316, a Novel, Selective WEE1/PKMYT1 Inhibitor, and the Identification of Actionable Resistan

Retrieved on: 
Mercredi, avril 10, 2024
IC50, AP3, Drug resistance, Proteomics, PDX, CDX, Cell cycle, PKMYT1, Patient, Medicine, WEE1, Neoplasm, ACRV, AACR, Drug development, Biomarker, Drug discovery, Therapy, Ovarian cancer, Pharmaceutical industry

WATERTOWN, Mass., April 10, 2024 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, Acrivon Predictive Precision Proteomics (AP3), today announced data from two posters that the company presented at the American Association for Cancer Research (AACR) Annual Meeting.

Key Points: 
  • “Uniquely enabled by AP3, we designed a selective and potent dual inhibitor of both WEE1 and PKMYT1, ACR-2316, designed for potent single agent activity.
  • We presented preclinical data showing its superior activity versus benchmark WEE1 and PKMYT1 single-agent inhibitors in multiple cancer models and look forward to advancing this compound into the clinic.
  • The complete responses observed with ACR-2316 in human tumor xenograft mouse models were associated with strong WEE1 and balanced PKMYT1 inhibition activity in tumors.
  • This corresponded with the subsequent upregulation of ACR-368 OncoSignature biomarkers, indicating that the OncoSignature assay can predict which ULDG sensitized tumors would be responsive to treatment with ACR-368.

NiKang Therapeutics Doses First Patient in a Phase 1/1b Study of NKT3447, an Oral, Selective Inhibitor of CDK2 Which Reduces Cyclin E Expression

Retrieved on: 
Lundi, avril 15, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CDK1, Phosphorylation, Safety, Cyclin-dependent kinase 2, Pharmacokinetics, Cell cycle, Patient, Endometrial cancer, Cyclin E, Standard of care, CDK2, Therapy, Cancer, Ovarian cancer, Pharmaceutical industry

NiKang Therapeutics Inc. (“NiKang”) is a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs.

Key Points: 
  • NiKang Therapeutics Inc. (“NiKang”) is a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs.
  • The Company announced today that the first patient has been dosed in a phase 1/1b, open-label, first-in-human dose escalation and expansion study of single agent NKT3447, a small molecule that inhibits cyclin-dependent kinase 2 (CDK2).
  • NKT3447 is designed to treat patients with cancers driven by cyclin E amplification or overexpression, which is present in many different tumor types.
  • The Phase 1/1b trial (NCT06264921) is designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity of NKT3447 in adult patients with advanced or metastatic solid tumors driven by cyclin E or CDK2.

Ractigen Therapeutics Announces FDA Approval for RAG-01, a First-in-Class saRNA Therapy for BCG-Unresponsive NMIBC

Retrieved on: 
Vendredi, avril 26, 2024
FDA, Food, RNA, Cell cycle, Growth, IND, Therapy, Patient, SaRNA, NMIBC, RNAa, Bladder cancer, Investigational New Drug

SUZHOU, China, April 26, 2024 /PRNewswire/ -- Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a groundbreaking saRNA therapy targeting non-muscle invasive bladder cancer (NMIBC).

Key Points: 
  • SUZHOU, China, April 26, 2024 /PRNewswire/ -- Ractigen Therapeutics, a leader in the development of small activating RNA (saRNA) therapeutics, announced today that the U.S. Food and Drug Administration (FDA) has approved the company's Investigational New Drug (IND) application for RAG-01, a groundbreaking saRNA therapy targeting non-muscle invasive bladder cancer (NMIBC).
  • This approval facilitates the launch of U.S. clinical trials, following the successful initiation of a Phase I trial in Australia.
  • "FDA IND approval for RAG-01 is a major achievement for Ractigen and a significant advancement for saRNA technology worldwide," said Dr. Long-Cheng Li, Founder and CEO of Ractigen Therapeutics.
  • This approval validates the potential of RAG-01 as a leading saRNA therapy and strengthens our position as innovators in RNA-based treatments."

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

Retrieved on: 
Mardi, avril 2, 2024
WEE1, Medication, Research, 2D, Cell death, DNA repair, Colorectal cancer, Patient, SAN, DNA, Cell cycle, 3D, Lung cancer, AACR, Cancer, Poster, Therapy, Pharmaceutical industry

Research demonstrated that the Company’s WEE1 inhibitor, azenosertib, exerts synergistic anti-tumor activity when combined with KRASG12C inhibitors.

Key Points: 
  • Research demonstrated that the Company’s WEE1 inhibitor, azenosertib, exerts synergistic anti-tumor activity when combined with KRASG12C inhibitors.
  • Our preclinical data demonstrate that combining azenosertib with KRASG12C inhibitors dramatically enhances anti-tumor activity.
  • The research that will be presented at AACR Annual Meeting 2024 evaluated the anti-tumor activity of azenosertib when administered in combination with KRASG12C inhibitors sotorasib or adagrasib.
  • The data demonstrated synergistic cell growth inhibition across a panel of KRASG12C cell lines in both 2D and 3D assays.

Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights

Retrieved on: 
Jeudi, mars 28, 2024
WEE1, Research, ACRV, Ovarian cancer, Carcinoma, Drug discovery, Patient, Neoplasm, Cell cycle, AP3, IC50, Proteomics, Abstract, AACR, PKMYT1, Clinical trial, Therapy, Toxicology, Mass spectrometry, GLP, Medicine, LDG, Pharmaceutical industry

“On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year for Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.

Key Points: 
  • “On the heels of a productive 2023, we are off to a tremendous start in 2024, which is an important and data-driven year for Acrivon,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon.
  • We remain on track to present more mature clinical data during the first half of 2024.
  • Additionally, our novel WEE1/PKMYT1 inhibitor ACR-2316 continues to demonstrate robust and superior single-agent preclinical activity and tolerability as demonstrated in head-to-head benchmark studies.
  • As of December 31, 2023, the company had cash, cash equivalents and marketable securities of $127.5 million, which is expected to fund operations into the fourth quarter of 2025.

Aprea Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update

Retrieved on: 
Mardi, mars 26, 2024
Ovarian cancer, Cyclin, IND, Therapy, Anemia, Research, University, Cell cycle, MD Anderson Cancer Center, PLK1, DDR, Investigational New Drug, Safety, Pharmacokinetics, Synthetic lethality, WEE1, U.S. FDA, Mutation, Acceleration, Part, HERG, ATR, KOL, Acquisition, Cancer, AACR, Research and development, Poster, FDA, Cyclin E, Toxicity, Aplastic anemia, Administration, Conference, APRE, PLK3, PLK2, Division, Data, Cardiotoxicity, Pharmaceutical industry

DOYLESTOWN, Pa., March 26, 2024 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE) (“Aprea”, or the “Company”), a clinical-stage biopharmaceutical company focused on precision oncology through synthetic lethality, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.

Key Points: 
  • “Aprea had a very productive 2023 with significant progress across our diversified pipeline of synthetic lethality-based cancer therapeutics.
  • An update from Part 1 of the trial was featured in a poster presentation at the AACR-NCI-EORTC International Conference in October 2023.
  • Select Financial Results for the Fourth Quarter ended December 31, 2023
    As of December 31, 2023, Aprea reported cash and cash equivalents of $21.6 million.
  • Research and Development (R&D) expenses were $2.0 million for the quarter ended December 31, 2023, compared to $0.5 million for the fourth quarter of 2022.

NiKang Therapeutics Presents the Discovery and Unique Mechanism of Action of a Selective CDK2 Inhibitor NKT3447 at AACR Annual Meeting 2024

Retrieved on: 
Vendredi, avril 5, 2024
Oncology, Health, Other Science, Clinical Trials, Research, Science, Biotechnology, CDK1, Phosphorylation, CDK2, CDK, Patient, Cell cycle, AACR, Therapy, Cancer, Safety, Pharmacokinetics, Cyclin E, Pharmaceutical industry

NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDKs, prolonged pharmacodynamic effects, and a distinct mechanism of action.

Key Points: 
  • NKT3447 is an orally bioavailable small molecule CDK2 inhibitor that exhibits high selectivity against CDK1 and other CDKs, prolonged pharmacodynamic effects, and a distinct mechanism of action.
  • It downregulates cyclin E and suppresses activating phosphorylation of CDK2 on Thr160.
  • “We are pleased to share the discovery of NKT3447, a highly selective CDK2 inhibitor with unique properties, at the AACR Annual Meeting”, said Zhenhai Gao, Ph.D., co-founder, president, and CEO of NiKang.
  • Discovery of a selective slow-off CDK2 inhibitor NKT3447 with distinct features of suppressing CDK2, downregulating cyclin E, and achieving prolonged pathway inhibition

Feinstein Institutes Secures $6.1M NIH Grant for Red Cell Disorder Research

Retrieved on: 
Mercredi, avril 3, 2024
Biotechnology, Health, Science, Pharmaceutical, Research, Diamond, Molecular medicine, Sickle cell disease, Erythropoiesis, Hematology, HMGB1, Cell cycle, Mortality, Doctor of Philosophy, Quality of life, NIH, Diamond–Blackfan anemia, DBA, Credit, Lung, SCD, Medical research, Anemia, Bangladesh Technical Education Board, Multimedia, Conditional sentence, Pharmaceutical industry

To further our understanding and potential treatments of these disorders, The Feinstein Institutes for Medical Research has been awarded a $6.1 million grant from the National Institutes of Health (NIH).

Key Points: 
  • To further our understanding and potential treatments of these disorders, The Feinstein Institutes for Medical Research has been awarded a $6.1 million grant from the National Institutes of Health (NIH).
  • View the full release here: https://www.businesswire.com/news/home/20240403646471/en/
    Dr. Lionel Blanc will lead the new NIH-funded red cell disorders research (Credit: Feinstein Institutes)
    Led by Lionel Blanc, PhD , professor in the Institute of Molecular Medicine at the Feinstein Institutes, the seven-year initiative aims to build off previous research and will shed light on DBA, SCD and anemia.
  • “Understanding red cell blood disorders, how they develop and progress, is essential given their global impact on millions,” said Dr. Blanc.
  • In 2019, he received a $2.5 million grant from the NIH to study treatment for erythropoietic disorders, including DBA.

New Tool Reveals Gene Behavior in Bacteria

Retrieved on: 
Mercredi, janvier 24, 2024
Death, ECG, DNA replication, Alfred P. Sloan Foundation, TRIPS Agreement, Heart, DNA, Ralph, Champaign–Urbana metropolitan area, Publishing, Gene, University, Medicine, Genetics, Environment, Tick, In situ hybridization, Bacteria, NYU, Human, Cell cycle, Disease, NYU Langone Health, Protein, Nature, Doctor of Philosophy, Genome, National Institutes of Health, Messenger, Gene expression, Bangladesh Technical Education Board, Pathogenic bacteria, TRIP, Cell, Vaccine

This is due in part to the ability of bacteria to switch genes on and off as they sense environmental changes, including the presence of drugs.

Key Points: 
  • This is due in part to the ability of bacteria to switch genes on and off as they sense environmental changes, including the presence of drugs.
  • According to the study authors, organisms from bacteria to humans grow as their cells multiply by dividing, with each cell becoming two.
  • Specifically, the research team found that when DNA polymerase arrives at any specific gene, it disrupts the transcription in a way that reveals the state of that gene's regulatory status.
  • Ultimately, they believe that improvements in technology will enable them to dive ever deeper into gene behaviors in different bacterial species.

Onconova Therapeutics’ ASH Poster To Focus on Narazaciclib in MCL

Retrieved on: 
Jeudi, novembre 2, 2023
Metabolomics, Cell cycle, Drug resistance, 65th Infantry Division (United States), Mantle cell lymphoma, Society, ASH, Lymphoid neoplasms with plasmablastic differentiation, MCL, G1 phase, Pharmacology, Differentiation, Cancer, Therapy, Patient, Pharmaceutical industry

NEWTOWN, Pa., Nov. 02, 2023 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX), (“Onconova” or “the Company”), a clinical-stage biopharmaceutical company focused on discovering and developing novel products for patients with cancer, today announced that Onconova and collaborators will present a preclinical poster related to its lead program, narazaciclib, at the 65th American Society for Hematology Annual Meeting & Exposition (ASH), taking place in San Diego, California from December 9 to 12, 2023.

Key Points: 
  • The experiments included a broad comparison of narazaciclib with three other approved cyclin-D-kinase inhibitors (CDKis), used in combination with several BTKis,” said Steven Fruchtman, M.D., President and CEO of Onconova.
  • Dr. Fruchtman continued, “We were especially pleased by the broad translational data set that provided an understanding of narazaciclib’s role in cell cycle blockade.
  • These studies show that narazaciclib appears to act in the G1 phase of the cell cycle.
  • Molecular Pharmacology and Drug Resistance: Lymphoid Neoplasms: Poster III